Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature CommunicationsPRNewsWire • 05/10/23
Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra TherapeuticsPRNewsWire • 04/18/23
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment StrategiesPRNewsWire • 03/29/23
Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational MedicinePRNewsWire • 03/21/23
Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short SellingPRNewsWire • 02/07/23
Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" PodcastPRNewsWire • 11/08/22
This SPAC is merging with an already-public company as sponsors get creative before time runs outCNBC • 06/09/22
Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid TumorsPRNewsWire • 05/17/22
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera BiopharmaPRNewsWire • 04/13/22
Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product DevelopmentPRNewsWire • 01/20/22